Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17846695 | 0.99 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL22268674 | 0.81 | HCRTR1 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL17846686 | 0.81 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL1319504 | 0.81 | HCRTR1 (0.53) | HCRTR1HCRTR2 | |
| SCHEMBL17858157 | 0.80 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL19689879 | 0.75 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL17858003 | 0.74 | CKS1B (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL17846747 | 0.74 | HCRTR1 (0.63) | HCRTR1HCRTR2 | |
| SCHEMBL17843154 | 0.74 | CCNC (0.41) | — | |
| SCHEMBL932647 | 0.73 | HCRTR1 (0.41) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170355692-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355692-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| WO-2016100161-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355692-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885 |
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.